Unveiling Remyelinating Properties of Roflumilast in CPZ-Induced Neuronal Demyelination in Mice

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) involves oligodendrocyte apoptosis and microglial activation, processes linked to phosphodiesterase-4 (PDE-4) activity.
• Roflumilast (ROFL), a selective PDE-4 inhibitor, has shown neuroprotection in CNS disorders, but its role in MS is unclear.

Purpose of the Study:

• Investigate ROFL's effects on oligodendrocyte maturation and microglial polarization in an MS model.
• Examine ROFL's impact on the protein kinase A/cAMP-response element binding protein pathway.

Main Methods:

• An MS mouse model was induced using cuprizone (CPZ) administration.
• Mice were treated with ROFL (5 mg/kg/day) during the later stages of cuprizone exposure.
• Behavioral tests, biochemical assays, and histological staining were performed.

Main Results:

• ROFL improved motor function and modulated the PDE4/cAMP pathway, reducing inflammation (NF-κB, TNF-α).
• Microglial polarization shifted to an anti-inflammatory M2 phenotype, and antioxidant capacity increased (reduced MDA, increased GSH).
• Oligodendrocyte differentiation and myelination were enhanced, with reduced apoptosis (caspase-3).

Conclusions:

• ROFL demonstrates neuroprotective effects in an MS model.
• PDE-4 inhibition via ROFL promotes remyelination and reduces neuroinflammation, suggesting therapeutic potential for MS.